A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04882631|
Recruitment Status : Completed
First Posted : May 12, 2021
Last Update Posted : January 27, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: PBI-100 Topical Cream Drug: Positive Control - Sodium laurel sulfate (SLS) Other: PBI-100 Topical Cream, Vehicle Other: Negative Control||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||The order of test product patch placement is randomized.|
|Masking:||None (Open Label)|
|Masking Description:||The participant and evaluator are blinded to the identity of the test product (3 strengths of PBI-100), vehicle, negative control and positive control placed on each subject's forearm, upper arm or back|
|Official Title:||A 21 Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants Using a Cumulative Irritant Patch Test Design|
|Actual Study Start Date :||April 12, 2021|
|Actual Primary Completion Date :||May 3, 2021|
|Actual Study Completion Date :||May 3, 2021|
Experimental: Cumulative Irritation Test
Participants will receive topical applications of three concentrations of PBI-100 Topical Cream, one application of vehicle, one application of sodium lauryl sulfate as a positive control and one application of a plain patch as a negative control daily (excluding weekends) for 21 days or 15 applications.
Drug: PBI-100 Topical Cream
A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
Drug: Positive Control - Sodium laurel sulfate (SLS)
Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
Other Name: SLS
Other: PBI-100 Topical Cream, Vehicle
Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
Other: Negative Control
A blank patch was applied daily (excluding weekends) as a negative control test site.
- Irritation Potential [ Time Frame: 21 days ]Irritation potential based on the Cumulative Irritation Index (CII)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Healthy adult male and female volunteers between the ages of 18 and 70 years with Fitzpatrick types I, II, or III.
- Must be willing to follow the study requirements and voluntarily give their informed consent.
- Subjects must be able to read and follow study instructions in English.
- Generally in good health as determined by the investigator, based on medical history interview.
- Evidence of a personally signed and dated Informed Consent indicating that the subject has been informed of and understood all pertinent aspects of the trial.
- Scars, moles, or other blemishes over the forearm, upper arm, or back that interfere with the study.
- Sunburn within the last three weeks or use of tanning beds.
- History of allergy or hypersensitivity to skin care or consumer products including fragrances, cosmetics, toiletries, or any kind of tape.
- History of chronic or recurrent dermatological diseases, e.g., psoriasis, atopic eczema, chronic urticaria.
- Subjects receiving systemic or topical drugs which can interfere with the development of an inflammatory response, e.g., steroids, immunosuppressive agents, or retinoids.
- History of any significant systemic diseases e.g., cardiac, pulmonary, renal, hepatic, etc. that would impact subject's ability to complete the study.
- Pregnancy or mothers who are breastfeeding or planning a pregnancy.
- Other conditions considered by the Investigator as sound reasons for disqualification from enrollment into the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04882631
|United States, Pennsylvania|
|KGL Skin Study Center|
|Newtown Square, Pennsylvania, United States, 19073|
|Study Director:||Chief Medical Officer||Pyramid Biosciences|
|Responsible Party:||Pyramid Biosciences|
|Other Study ID Numbers:||
|First Posted:||May 12, 2021 Key Record Dates|
|Last Update Posted:||January 27, 2022|
|Last Verified:||January 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|